Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants
Background There is a paucity of evidence regarding the effects of non-vitamin K antagonist
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …
[HTML][HTML] Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …
[HTML][HTML] Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ED Peterson, V Ashton, YW Chen, B Wu… - American heart …, 2019 - Elsevier
Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …
Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual …
BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …
Association between body mass index and clinical outcomes in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants: a new piece of …
S Wu, N Huang, X Chen, S Jiang, W Zhang… - … Drugs and Therapy, 2023 - Springer
Purpose We conducted a multicenter real-world study in China to assess the association
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …
Use of direct oral anticoagulants in morbidly obese patients
K Kido, JC Lee, T Hellwig… - … : The Journal of Human …, 2020 - Wiley Online Library
In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …
[HTML][HTML] Risks and benefits of oral anticoagulants for stroke prophylaxis in atrial fibrillation according to body mass index: nationwide cohort study of primary care …
YM Nakao, K Nakao, J Wu, R Nadarajah… - …, 2022 - thelancet.com
Summary Background Direct oral anticoagulants (DOACs) are effective and safe alternatives
to warfarin for stroke prophylaxis for atrial fibrillation (AF). Whether this extends to patients at …
to warfarin for stroke prophylaxis for atrial fibrillation (AF). Whether this extends to patients at …
Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real‐world analysis
Y Chugh, K Gupta, HB Krishna… - Pacing and Clinical …, 2023 - Wiley Online Library
Background Atrial fibrillation and heart failure are combined risk factors for thromboembolic
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …
Efficacy and safety of direct oral anticoagulants for atrial fibrillation across body mass index categories
RM Kaplan, Y Tanaka, RS Passman… - Journal of the …, 2020 - Am Heart Assoc
Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …